Tavo 103
Alternative Names: Tavo-103Latest Information Update: 19 Dec 2023
At a glance
- Originator Tavotek Biotherapeutics
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Autoimmune disorders; Cancer
Most Recent Events
- 08 Jun 2023 Tavotek Biotherapeutics completes a phase I trial (In volunteers) in USA (IV, Infusion) (NCT05313152)
- 06 Apr 2022 Tavotek Biotherapeutics plans a phase I trial (In volunteers) in USA (IV, Infusion) (NCT05313152)
- 01 Aug 2021 Tavo 103 is available for licensing as of 01 Aug 2021. https://tavotek.com/about-us (Tavotek Biotherapeutics pipeline, August 2021)